Dipeptidyl peptidase IV inhibition downregulates Na\(^+\)-H\(^+\) exchanger NHE3 in rat renal proximal tubule

Adriana Castello Costa Girardi, Lívia Emy Fukuda, Luciana Venturini Rossoni, Gerhard Malnic, and Nancy Amaral Rebouças

Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil

Submitted 12 April 2007; accepted in final form 6 December 2007

Girardi AC, Fukuda LE, Rossoni LV, Malnic G, Rebouças NA. Dipeptidyl peptidase IV inhibition downregulates Na\(^+\)-H\(^+\) exchanger NHE3 in rat renal proximal tubule. Am J Physiol Renal Physiol 294: F414–F422, 2008.—In the microvillar microdomain of the kidney brush border, sodium hydrogen exchanger type 3 (NHE3) exists in physical complexes with the serine protease dipeptidyl peptidase IV (DPPIV). The purpose of this study was to explore the functional relationship between NHE3 and DPPIV in the intact proximal tubule in vivo. To this end, male Wistar rats were treated with an injection of the reversible DPPIV inhibitor Lys[Z(NO\(_2\)]-pyrrolidide (I40; 60 mg·kg\(^{-1}\)·day\(^{-1}\)·ip) for 7 days. Rats injected with equal amounts of the noninhibitory compound Lys[Z(NO\(_2\)]-OH served as controls. Na\(^+\)-H\(^+\) exchange activity in isolated microvillar membrane vesicles was 45 ± 5% decreased in rats treated with I40. Membrane fractionation studies using isopycnic centrifugation revealed that I40 provoked redistribution of NHE3 along with a small fraction of DPPIV from the apical enriched microvillar membranes to the intermicrovillar microdomain of the brush border. I40 significantly increased urine output (67 ± 7%; P < 0.01), fractional sodium excretion (63 ± 7%; P < 0.01), as well as lithium clearance (81 ± 9%; P < 0.01), an index of end-proximal tubule delivery. Although not significant, a tendency toward decreased blood pressure and plasma pH/HCO\(_3^-\) was noted in I40-treated rats. These findings indicate that inhibition of DPPIV catalytic activity is associated with inhibition of NHE3-mediated NaHCO\(_3^-\) reabsorption in rat renal proximal tubule. Inhibition of apical Na\(^+\)-H\(^+\) exchange is due to reduced abundance of NHE3 protein in the microvillar microdomain of the kidney brush border. Moreover, this study demonstrates a physiologically significant interaction between NHE3 and DPPIV in the intact proximal tubule in vivo.

sodium transport; proton secretion; fluid reabsorption; serine protease


Numerous physiological and humoral factors were reported to affect NHE3 activity, and although many of them share the same signaling pathways, their final response may differ greatly (7, 32). The recent identification of regulatory proteins that interact with NHE3 has unraveled some aspects of the molecular mechanisms underlying the transporter regulation (8, 32). By means of coprecipitation experiments, Girardi and colleagues (11) previously demonstrated that NHE3 exists in physical complexes with dipeptidyl peptidase IV (DPPIV) in brush-border membranes isolated from proximal tubule cells. In contrast to the NHE3-megalin complex (3), which principally resides in the intermicrovillar region of the brush border, a microdomain in which NHE3 is suggested to be inactive (2) or plays a distinct physiological role (10), the NHE3-DPPIV complex distributes mostly in the microvillar microdomain where NHE3 normally functions (11). These findings raised the possibility that association with DPPIV may affect NHE3 surface expression and/or activity.

DPPIV, also known as CD26, is a membrane-associated protein that is widely distributed in numerous tissues, including epithelial and endothelial cells and lymphocytes (42). A soluble form of the peptidase is also present in plasma and other body fluids (23). DPPIV acts by selectively removing NH\(_2\)-terminal dipeptides from oligopeptides with a penultimate proline or alanine (19). Through this action, it is able to degrade and inactivate several regulatory peptides including peptide hormones (e.g., glucagon-like peptide-1, glucagon-dependent insulinotropic polypeptide, bradykinin), neuropeptides (e.g., substance P, neuropeptide Y), and chemokines (e.g., RANTES, eotaxin) so that its activity is important for many different physiological processes (23, 30).

Inhibitors of DPPIV catalytic activity represent a new class of oral antihyperglycemic agents for the treatment of type 2 diabetes mellitus. The usefulness of these inhibitors rests on their ability of preventing the DPPIV-mediated rapid degradation of glucagon-like peptide-1 which is known to have a number of positive effects on glucose homeostasis including stimulation of glucose-dependent insulin secretion, suppression of glucagon secretion, and slowing of gastric emptying (29). Although used routinely, the renal effects of these inhibitors have not been well-characterized.

It has been previously reported that specific competitive inhibitors that bind to the active site of DPPIV reduce NHE3 activity in cultured opossum kidney proximal tubule (OKP) cells (12). This, in turn, implies that DPPIV enzyme activity plays a tonic role in modulating NHE3 in OKP cells. It is therefore of interest to explore the functional relationship between NHE3 and DPPIV in the native proximal tubule. The purpose of this study was to test the hypothesis that DPPIV, by virtue of its oligomeric association with NHE3, directly or indirectly affects NHE3 activity in the intact proximal tubule in vivo. We demonstrate that administration of the reversible DPPIV inhibitor Lys[Z(NO\(_2\)]-pyrrolidide (34, 37, 39, 40) is
associated with inhibition of NHE3-mediated NaHCO3 resorption in the rat renal proximal tubule. Furthermore, our data demonstrate that there exists an in vivo functional interaction between NHE3 and DPPIV.

MATERIALS AND METHODS

Reagents and antibodies. Reagents were obtained from Sigma (St. Louis, MO) unless otherwise specified. DPPIV inhibitor Lys[Z(NO2)3]-pyrrolidide (140) and the noninhibitory structurally related compound Lys[Z(NO2)3]-OH were purchased from Bachem (Philadelphia, PA). 22Na and [53P]phosphoric acid were obtained from New England Nuclear Life Sciences Products (Boston, MA). A monoclonal antibody (mAb) raised to the renal brush-border Na+/H+ exchanger (NHE3), clone 2B9 (5), was purchased from Chemicon International (Temecula, CA). A monoclonal antibody to rat DPPIV, clone SE8, was purchased from Cell Sciences (Canton, MA). A mAb to actin (JLA20) was purchased from Calbiochem (San Diego, CA). Horse-radish peroxidase-conjugated goat anti-mouse, goat anti-rabbit, and rabbit anti-goat secondary antibodies were purchased from Zymed Laboratories (San Francisco, CA).

Animal preparation. All animal experiments were approved by the Institute of Biomedical Sciences, University of São Paulo, and conducted in accordance with the guidelines for the care and use of laboratory animals stated by the Brazilian Societies of Experimental Biology. Experiments were performed using male Wistar rats (190–240 g) obtained from the Institute of Biomedical Sciences of the University of São Paulo. Animals had free access to water and standard laboratory chow. Lys[Z(NO2)3]-pyrrolidide and the noninhibitory structurally related compound Lys[Z(NO2)3]-OH were provided in the lyophilized form. For the experiments described, the compounds were dissolved in PBS (10 mM) and adjusted to neutral pH. We administered to experimental rats an injection of 60 mg/kg body weight of the DPPIV inhibitor Lys[Z(NO2)3]-pyrrolidide (140) for 7 days. Rats injected with equal amounts of the noninhibitory compound Lys[Z(NO2)3]-OH served as controls. The concentration of 140 administrated was based on the experiments performed by Steinbrecher et al. (39). For the last 24 h, treated and control rats were maintained in metabolic cages for urine collection. Additionally, some studies were performed in which animals were individually housed in metabolic cages throughout the 7-day treatment. Food and water consumption were determined daily and subsequently normalized by body weight. Arterial blood was collected from the carotid at the time of death for measurements of blood pH, blood bicarbonate concentration, and PCO2. Plasma was also collected to determine concentrations of sodium, potassium, lithium, and creatinine.

Blood and urine analysis. pH, bicarbonate concentration, and PCO2 were measured on a Radiometer ABL5 blood gas analyzer (Radiometer, Copenhagen, Denmark). Sodium and potassium concentrations were measured on a 9180 Electrolyte Analyzer (Roche Diagnostics, Mannheim, Germany). Flame photometry (Micronal B262, São Paulo, SP, Brazil) was performed to obtain lithium concentration. Plasma and urine creatinine were measured on a Beckman Coulter Synchron CX7 Analyzer (Beckman Coulter, Fullerton, CA).

Arterial pressure and heart rate determinations. Immediately after administration of the last dose of 140 or its inactive analog, rats underwent anesthesia with ketamine-xylazine-acepromazine (64.9, 3.20, and 0.78 mg/kg ip). The right carotid artery was catheterized with a polyethylene catheter (PE-50, 8 cm, filled with heparinized saline) that was exteriorized in the midscapular region. After recovery, rats were placed in individual cages. Twenty-four hours later, arterial pressure and heart rate were measured in conscious animals. Arterial blood pressure was measured by a pressure transducer (model Deltran DPT-100, Utah Medical Products, Midvale, UT) connected to an amplifier (model AECAD-0804, Solução Integrada, São Paulo, SP, Brazil) and recorded using an interface and software for computer data acquisition (model DI-194RS WinDat, DataQ Instruments, Akron, OH). Heart rate was determined from the pressure pulse intervals.

Enzyme assays. Both DPPIV (17) and γ-glutamyl transpeptidase (γ-GTP) (41) activities were assayed in kidney homogenates by measuring the release of p-nitroaniline resulting from the hydrolysis of glycylylproline p-nitroanilide tosylate and γ-glutamyl p-nitroanilide (Sigma), respectively. DPPIV activity was measured by incubating 10 μl of kidney homogenates with 100 μl of phosphate saline buffer, pH 7.4, containing 2 mM glycylylpropyl-p-nitroanilide tosylate for 30 min at 37°C. The mixture was incubated for 30 min at 37°C. The reaction was terminated by the addition of 300 μl 1 M acetate buffer, pH 4.2. For the γ-GTP assay, 10 μl of kidney homogenates were added to the 2-mL reaction mixture containing 4.2 mM L-γ-glutamyl-p-nitroanilide, 52.5 mM glycglycine, 10.5 mM MgCl2 in 50 mM ammidiol buffer, pH 9.3, and incubated for 5 min at 25°C. Determination of p-nitroaniline liberated enzymatically was based on the absorbance at 380 nm. Catalytic activities are expressed as milliunits per milligram of protein, where one unit of enzymatic activity was defined as the amount of enzyme required for the formation of 1 μM p-nitroaniline per minute under the conditions described.

Microvillar membrane vesicle preparation. Immediately after kidney removal, cortices were separated at 4°C and homogenized in K-HEPES buffer (200 mM mannitol, 80 mM HEPES, 41 mM KOH, pH 7.4, containing the protease inhibitors pepstatin A (0.7 μg/ml), leupeptin (0.5 μg/ml), PMSF (40 μg/ml), and K2EDTA (1 mM). Microvillar membrane vesicles (MMV) were prepared using a method based on Mg2+ precipitation and differential centrifugation as previously described (6). Protein concentration was measured by the method of Lowry (27). Rat MMV preparations used in this study were 11- to 14-fold enriched in specific activity of the brush-border membrane marker enzyme γ-GTP relative to kidney homogenates.

Preparation of renal membrane fractions. Renal cortex was dissected cold from recently excised kidneys. Postmitochondrial microsomes were prepared and separated on 15–25% OptiPrep (Nycomed Pharma, Oslo, Norway) gradients essentially as described previously (2, 21). One-milliliter fractions were manually collected from the top and assayed for the presence of vH-HO3 (H-60, Santa Cruz Biotechnol- ogy, Santa Cruz, CA) and megalin (H-245, Santa Cruz Biotechnol- ogy) by immunoblotting. Fraction 1 which was enriched in the microvillar membrane marker villin (low-density gradient fraction) was pelleted by centrifugation and resuspended in K-HEPES buffer. High-density fractions, which were enriched in megalin, but not villin, were pooled from fractions 5–6 in the gradient, pelleted, and then resuspended in K-HEPES buffer. The low- and high-density gradient fractions were stored at −80°C. Protein concentration was measured by the method of Lowry et al. (27).

Radioactive sodium uptake. Uptake of 22Na into the membrane vesicles was assayed at room temperature using a rapid filtration technique (28). MMV were washed and equilibrated for 1 h at room temperature in 254 mM mannitol, 35 mM KOH, 68 mM HEPES, 50 mM Mes, pH 6.0. The vesicles were then centrifuged and resuspended in the same medium at a final protein concentration of 10 μg/ml. Uptake experiments were then performed in triplicate by the addition of 10 μl of membrane suspension to 90 μl of experimental solution containing 4 × 105 cpm 22Na, 300 mM mannitol, 42 mM KOH, 80 mM HEPES, pH 7.5. After incubation for 15 s at room temperature, the reaction was terminated by rapid addition of 3.0 ml of an ice-cold “stop solution” consisting of 300 mM mannitol, 42 mM KOH, 80 mM HEPES, pH 7.5. The mixture was immediately poured on a 0.65-μm Millipore filter and washed with an additional 9.0 ml of “stop solution.” Filters were then placed in vials containing 3.0 ml Ready Solv HP (Beckman) and counted by scintillation spectroscopy. Values for the nonspecific retention of 22Na by the filters were subtracted from the values for the incubated samples. Some experiments were performed in the presence of 100 μM EIPA to inhibit NHE3 activity.

Sodium-dependent phosphate uptake assays. Uptake of 32P-radio- labeled phosphoric acid was measured at room temperature using a
rapid Millipore filtration technique (20). MMV were suspended in a sodium-free medium containing 300 mM mannitol, HEPES-Tris, pH 7.4. Uptake was initiated by mixing 10 µl MMV suspension with 40 µl of transport medium that comprised of 100 mM mannitol, 100 mM NaCl, HEPES-Tris, and 3²P-radiolabeled phosphoric acid (2 µCi/ml). To determine non-Na\(^+\) gradient-dependent or diffusive phosphate uptake, 100 mM NaCl was replaced with 100 mM KCl. Uptake was terminated after 10 s by aspiration of the transport medium and washing the cells with ice-cold sodium-free medium. Radioisotopic activity was determined by liquid scintillation spectroscopy. Non-specific retention of ³²PO₄ was determined and subtracted from the values for the incubated samples.

SDS-PAGE and immunoblotting. Protein samples were solubilized in SDS sample buffer and separated by SDS-PAGE using 7.5% polyacrylamide gels according to Laemmli (22). For immunoblotting, proteins were transferred to polyvinylidene difluoride (PVDF; Immobilon-P; Millipore, Bedford, MA) from polyacrylamide gels at 500 mA for 5 h at 4°C with a Transphor transfer electrophoresis unit (Hoefer Scientific Instruments, San Francisco, CA) and stained with Ponceau S in 0.5% trichloroacetic acid. Entire sheets of PVDF (Hoefer Scientific Instruments, San Francisco, CA) were used to calculate significance. The program “Graph Pad Prism 4” (Graph Pad Software, San Diego, CA) was used to calculate significance.

RESULTS

Effect of DPPIV inhibition on NHE3 activity in rat renal proximal tubule. For this study, we administered to experimental rats an injection of 60 mg·kg\(^{-1}\)·day\(^{-1}\) ip of the highly specific DPPIV inhibitor I40 (34, 37, 39, 40). Rats injected with equal amounts of the noninhibitory compound Lys[Z(NO₂)]-OH served as controls (39). As mentioned earlier, DPPIV is a serine protease that cleaves NH₂-terminal dipeptides from peptides with a penultimate proline or alanine (19). Based on the structural similarity of pyrrolidide to proline, I40 is a dipeptide product analog with high affinity (K\(_i\) = 0.271 ± 0.012 µM) for binding to the active site and inhibiting DPPIV (37, 40).

After 7 days of treatment with I40, DPPIV catalytic activity was assayed in kidney homogenates. As seen in Fig. 1, DPPIV enzyme activity in renal homogenates was 257 ± 12 mU/mg protein in control rats, whereas in I40-treated rats it was only 40 ± 7 mU/mg protein (P < 0.0001). In contrast, activity of
another proximal tubule apical membrane enzyme, γ-GTP, did not change in rats treated with the DPPIV inhibitor compared with control rats ($P = 0.75$).

To examine the possible role of DPPIV in modulating NHE3 activity in vivo, $\text{Na}^+\text{-H}^+$ exchange activity was assayed in renal MMV prepared from untreated (rats administered PBS, $n = 4$), control (rats administered I40-inactive analog, $n = 8$), and I40-treated rats ($n = 8$). The results of these experiments are shown in Fig. 2A. The noninhibitory I40 structurally related compound had no effect on $\text{Na}^+\text{-H}^+$ exchange mediated by NHE3 compared with rats that received vehicle (PBS; $P > 0.05$). Conversely, NHE3 activity was significantly reduced in I40-treated rats ($962 \pm 111 \text{ pmol} \cdot \text{mg}^{-1} \cdot \text{min}^{-1} \cdot \text{s}^{-1}$) relative to both control ($1,827 \pm 119 \text{ pmol} \cdot \text{mg}^{-1} \cdot \text{min}^{-1} \cdot \text{s}^{-1}$) and untreated rats ($1,752 \pm 194 \text{ pmol} \cdot \text{mg}^{-1} \cdot \text{min}^{-1} \cdot \text{s}^{-1}$; $P < 0.001$ and $P < 0.01$, respectively). No significant difference among these groups was observed when MMV were assayed in the presence of 100 μM EIPA.

To verify the specificity of the effect of DPPIV inhibition on NHE3 activity, we evaluated whether treatment with I40 would affect the activity of another apical membrane sodium-dependent transporter, the Na-phosphate cotransporter, which had previously found not to be associated with DPPIV (11). Na-phosphate cotransporter activity was measured as $^{32}$P-radiolabeled phosphate uptake in the presence of sodium. As indicated in Fig. 2B, no detectable difference was observed in the sodium-dependent component of radiolabeled phosphate uptake in the presence of the DPPIV inhibitor I40.

Taken together, these results indicate that DPPIV enzyme activity in renal tissue is markedly reduced by treatment with I40. The inhibition of the catalytic site of DPPIV specifically decreases NHE3 activity by $\sim 45\%$ in rat renal proximal tubule.

**Effect of DPPIV inhibitor I40 on NHE3 expression in rat renal proximal tubule.** We next examined whether the effect of I40 to reduce NHE3 activity is due to changes in expression and subcellular localization of NHE3.

MMV isolated by divalent cation precipitation were subjected to SDS-PAGE and immunoblotting. As indicated in Fig. 3, DPPIV inhibition led to decreased abundance of MMV-NHE3. Densitometric analyses, corrected to actin expression used as internal control, revealed a decrease of $51 \pm 6\%$ on renal microvillar NHE3 protein content, compared with the control group (Fig. 3B). Interestingly, not only NHE3 protein expression is downregulated by the inhibition of DPPIV activity but also the expression of DPPIV itself. As seen in the representative immunoblot (Fig. 3A), and confirmed by densitometry (Fig. 3C), I40 treatment induced a $27 \pm 5\%$ decrement on MMV-DPPIV protein levels.

Biemesderfer and colleagues (2) previously showed that NHE3 exists as (at least) two oligomeric forms that are differentially localized to distinct microdomains of the kidney brush border. Approximately 50% of the transporter has a sedimentation coefficient of 9.6S and is enriched in the microvillar membrane. In contrast, the remainder of the NHE3 protein has a sedimentation coefficient of 21S and principally resides in the intermicrovillar cleft region of the kidney brush border (2). Considering these findings, we sought to test the hypothesis that decrement of MMV-NHE3 protein content in response to DPPIV inhibition may possibly be caused by redistribution of NHE3 from the microvillus to the intermicrovillar fraction of kidney brush border. For this purpose, we performed immu-

Fig. 3. Effect of DPPIV inhibition on NHE3 and DPPIV protein expression levels in rat renal microvillar membranes. A: MMV were prepared by divalent cation aggregation from rats treated with I40 or the noninhibitory compound Lys[Z(NO$_2$)$_2$]-OH (control) for 7 days. Equal amounts of MMV (25 μg protein) were subjected to SDS-PAGE, transferred to a PVDF membrane, and analyzed by immunoblotting. Blots were probed with antibodies to NHE3, DPPIV, and actin (as loading control). Densitometry values for NHE3 (B) and DPPIV (C) were normalized with actin and plotted as a bar graph. Results are expressed as % of control. Values are means ± SE. *$P = 0.0003$ and **$P = 0.01$ vs. control as determined by unpaired $t$-test.
nblotting experiments (Fig. 4) using equal quantities (25 μg protein) of a light-density gradient fraction enriched in microvillar membrane proteins (MMV) and a high-density fraction enriched in intermicrovillar membrane proteins (IMV) isolated by density fractionation of total renal cortical membranes. As shown in Fig. 4, A and B, sustained inhibition of DPPIV activity induced a decrease of 51 ± 7% (MMV-I40 vs. MMV-CTRL, P < 0.05) on NHE3 expression in the microvillar-enriched fraction paralleled by an increase of 73 ± 8% (IMV-I40 vs. IMV-CTRL, P < 0.001) on the transporter abundance in the intermicrovillar membrane-enriched fraction. A similar pattern of redistribution was observed for DPPIV (Fig. 4, A and C).

We also analyzed the effect of DPPIV inhibition on total cortical expression of both NHE3 and DPPIV. As illustrated in Fig. 5, nonsignificant differences were found for NHE3 (P = 0.07; I40 vs. CTRL) and DPPIV (P = 0.71; I40 vs. CTRL) total kidney cortical expression in response to a 7-day treatment with the reversible DPPIV inhibitor I40.

Based on these findings, we conclude that reduction in NHE3 activity is due to its retraction out of the apical-enriched microvillar membrane microdomain of the kidney brush border. The NHE3-associated protein DPPIV redistributes to the intermicrovillar membrane-enriched fraction along with NHE3 indicating a functional interaction between these two proteins in rat renal proximal tubule.

Effect of DPPIV inhibition on renal tubular handling of sodium, fluid, and bicarbonate. Having demonstrated that inhibition of NHE3 in the intact proximal tubule is associated with the decrease in DPPIV catalytic activity, we next verified whether differences with respect to sodium, fluid, and bicarbonate reabsorption could be observed between I40-treated and control rats.

Rats treated with the DPPIV inhibitor I40 for 7 days had significantly increased urine output compared with control rats (I40-treated rats: 39 ± 3 vs. control rats: 65 ± 8 ml/kg body wt; P < 0.01) during the collection period of 24 h (Fig. 6A). In parallel, the increase in urine output was accompanied by a significant increase in water intake (Table 1). As depicted in Fig. 6C, I40-treated rats exhibited a significantly higher fractional sodium excretion compared with control rats (0.88 ± 0.11 vs. 0.54 ± 0.04% in control rats; P < 0.01). As seen in Table 1, no increment on food intake was observed between the two groups. In fact, rats administered I40 gain less weight throughout the 7-day period of treatment compared with controls. Whether this effect is due to a transient negative sodium balance is unknown. Of note, some reports showed that long-term treatment with DPPIV inhibitors may cause reduction in body weight gain (33). Nonetheless, to fully address this aspect, a detailed metabolic analysis should be carried out which is beyond the scope of this study.

Blood samples taken after the 7-day treatment period yielded the data presented in Table 2. There were no significant differences between the two groups of animals with respect to any of the blood variables measured. Also, creatinine clearance was unaltered between treated animals and controls (5.5 ± 0.2 vs. 6.0 ± 0.3 ml·min⁻¹·kg body wt⁻¹ in controls; P = 0.11) suggesting that glomerular filtration rate was not significantly affected by DPPIV inhibition (Fig. 6B).

On the basis that filtered lithium ions are reabsorbed exclusively in proximal tubule, in proportion to the reabsorption of
sodium and water, lithium clearance (CLi) is widely used as a measure of end-proximal tubule delivery (43). We found that CLi was significantly higher in rats treated with I40 (3.8 ± 0.5 ml/min/100 kg body wt vs. 2.1 ± 0.1 ml/min/185 kg body wt in controls; \( P < 0.01 \); Fig. 6D). Thus impairment in sodium and water reabsorption caused by DPPIV inhibition occurs predominantly, if not exclusively, in the kidney proximal tubule.

Renal sodium homeostasis is one of the major determinants for blood pressure levels. Na\(^{+}\)-H\(^{+}\) exchange is the major route for apical sodium entry across the proximal tubule, and the NHE3 isoform is responsible for virtually all the Na\(^{+}\)-H\(^{+}\) exchange activity in this region (1, 4, 5, 26, 38, 44–46). The present results demonstrated that although there was a tendency for reduced systolic (≈5%), diastolic (≈6%), and mean (≈5%) arterial pressures in rats treated with the DPPIV inhibitor I40, this decrease was not statistically significant (Table 2). No significant differences were also observed in heart rate between these two groups of rats (Table 2).

Table 3 summarizes the effect of DPPIV inhibition on plasma and urine acid-base composition. Urine analyses re-
isolated MMV. Inhibition of microvillar membrane Na\textsuperscript{+}-test. \((n/H11005\) food and water intake were made every day and normalized by body weight \([Z(NO2)]\)-pyrrolidide reduces Na\textsuperscript{+} found that 7-day treatment with the DPPIV inhibitor Lys\([Z(NO2)]\)-OH (control).

NHE3 activity is controlled tightly by several molecular mechanisms, including interaction with binding partner proteins. The biochemical and physiological characterization of these interactions using in vitro and in vivo models will certainly provide new understanding of sodium, bicarbonate, and fluid transport by the kidneys. In the present report, we examined the functional significance of the association of NHE3 with DPPIV in the native rat renal proximal tubule. We found that 7-day treatment with the DPPIV inhibitor Lys\([Z(NO2)]\)-pyrrolidide reduces Na\textsuperscript{+}-\textsuperscript{H}\textsuperscript{+} exchange activity in isolated MMV. Inhibition of microvillar membrane Na\textsuperscript{+}-\textsuperscript{H}\textsuperscript{+} exchange is mainly due to changes in the subcellular localization of NHE3.

The renal brush border is composed of two microdomains that are structurally and functionally distinct (35). The microvillar microdomain consists of villin-rich, actin-based cores that serve to amplify the apical proximal tubule surface area enhancing its capacity to transport substances present in the luminal fluid. At the base of the brush border, the plasma membrane invaginates into the cytoplasm forming the intermicrovillar cleft region. The intermicrovillar microdomain is enriched in megalin and is involved in mediating the initial steps of endocytic internalization in these cells (35). Immuno-precipitation experiments using monoclonal antibodies directed to either DPPIV or megalin have revealed that the pools of NHE3 complexed with DPPIV and megalin are largely distinct. Whereas NHE3-DPPIV complexes predominately reside in the microvilli (11), NHE3-megalin complexes are mainly present in the intermicrovillar clefts (2, 3). Our results indicate that long-term inhibition of DPPIV activity in rats leads NHE3 to shift to the megalin-enriched microdomain. Interestingly, a similar shift in the distribution of DPPIV itself was found in I40-treated rats confirming a functional link between these proteins. These findings are in agreement with a series of studies performed by the laboratory of Dr. A. Mc-Donough in which NHE3 along with DPPIV are coordinately redistributed between the microdomains of the kidney brush border in response to both acute (25, 49) and chronic stimuli (48, 50).

The precise physiological role of NHE3 in the intermicrovillar domain is difficult to ascertain. Studies by Biemesderfer and colleagues (3) suggest that NHE3 may be inactive when it is complexed with megalin. On the other hand, Yang et al. (47) showed that NHE3 is active in high-density gradient fractions that are enriched in megalin but not villin. It has also been demonstrated in vitro using OK cells that NHE3 plays a role in the initial endosomal acidification necessary for receptor-mediated albumin internalization (10). Anyhow, it appears to be consensual that the pool of NHE3 located in the intermicrovillar region of the brush border is not primarily involved with sodium reabsorption. Therefore, shifts in NHE3 redistribution have important consequences for the regulation of salt and water reabsorption by the renal proximal tubule.

Currently, several DPPIV inhibitors are undergoing clinical trials to evaluate the usefulness of these agents for the treatment of type 2 diabetes mellitus (DM2). The therapeutic utility of the DPPIV inhibitors rests mainly on their ability to prolong the half-life of insulin-releasing hormones (incretins), including glucagon-like peptide 1 (GLP-1) and the glucose-dependent insulinotropic hormone (GIP) (29). Every year an increasing number of studies are published evaluating the clinical efficacy and tolerability of these inhibitors in patients with
DM2. To the authors’ knowledge, this is the first report describing the renal effects of DPPIV inhibition. We found that rats treated with the DPPIV inhibitor I40 for 7 days present an increase in fractional sodium excretion (65%). Sodium influx provides the principal driving force for reabsorption of water in the proximal tubule cell, and a reduction in sodium reabsorption is coupled with a reduction in water reabsorption. Accordingly, DPPIV inhibition increases urine output by ~70%.

Despite the fact that increases in urine output and fractional sodium excretion were associated with DPPIV inhibition, no statistically significant differences with respect to blood pressure were observed in I40-treated animals. This may be explained by the existence of compensatory mechanisms such as upregulation of the renin-angiotensin-aldosterone system, as observed in mice lacking the NHE3 Na\(^{+}\)-H\(^{+}\) exchanger, that limit gross perturbations in overall volume homeostasis (38).

With regard to systemic acid-base status, I40-treated rats had slight decreases in blood pH and bicarbonate concentration. However, under our experimental conditions, these changes did not reach statistical significance. These observations are consistent with a partial inhibition of NHE3-mediated proton secretion. Since DPPIV does not seem to affect later nephron segments, reduction of NHE3 activity in proximal tubule may be fully compensated by increased urinary acid excretion and bicarbonate regeneration at downstream segments preventing the occurrence of acid-base disorders. Accordingly, urinary pH fell significantly in the I40-treated group.

The affector mechanisms by which DPPIV inhibition reduces NHE3 function are yet to be established. DPPIV is known to degrade a variety of peptide hormones, cytokines, and chemokines (23, 30). Accordingly, there is a high likelihood that DPPIV catalytic activity exerts a tonic role in stimulating NHE3 by processing an inhibitory peptide involved in regulation of the transporter. The effect of DPPIV inhibition on NHE3 activity might thereby be mediated by increasing the half-life of this candidate peptide. One such candidate is the DPPIV substrate GLP-1. GLP-1 is a gastrointestinal hormone secreted into the circulation in response to ingested nutrients. GLP-1 produces multiple physiological effects including enhancement of glucose-mediated insulin secretion, inhibition of glucagon release, promotion of satiety, and inhibition of gastric bicarbonate regeneration at downstream segments preventing the occurrence of acid-base disorders. Accordingly, urinary pH fell significantly in the I40-treated group.

The affector mechanisms by which DPPIV inhibition reduces NHE3 function are yet to be established. DPPIV is known to degrade a variety of peptide hormones, cytokines, and chemokines (23, 30). Accordingly, there is a high likelihood that DPPIV catalytic activity exerts a tonic role in stimulating NHE3 by processing an inhibitory peptide involved in regulation of the transporter. The effect of DPPIV inhibition on NHE3 activity might thereby be mediated by increasing the half-life of this candidate peptide. One such candidate is the DPPIV substrate GLP-1. GLP-1 is a gastrointestinal hormone secreted into the circulation in response to ingested nutrients. GLP-1 produces multiple physiological effects including enhancement of glucose-mediated insulin secretion, inhibition of glucagon release, promotion of satiety, and inhibition of gastric emptying (9, 18). Renal effects of GLP-1 have been documented by several recent studies undertaken in primary porcine proximal tubular cells (36), rats (24, 31), and humans (15, 16). Intravenous infusion of pharmacological doses of GLP-1 induces a diuretic and natriuretic response by decreasing sodium reabsorption in the proximal tubule (15, 16, 31). Interestingly, in healthy and insulin-resistant obese subjects GLP-1 infusion not only increases sodium excretion but also reduces proton secretion, implicating a direct effect of GLP-1 on Na\(^{+}\)-H\(^{+}\) exchange (15).

Each protein typically has a large number of alternative interaction partners and the selectivity of these interactions determines its responses to extracellular stimuli. It is of interest to mention that on the surface of the highly invasive 1-LN human prostate tumor cell line, plasminogen type II (Pg 2) forms a multimeric complex with both NHE3 and DPPIV. Pg 2 binding to DPPIV in this cell type induces an intracellular calcium signaling cascade that is accompanied by a rise in intracellular pH. The authors postulated that the interaction of Pg 2 with DPPIV and NHE3 has the potential to regulate simultaneously calcium signaling and Na\(^{+}\)-H\(^{+}\) exchange necessary to tumor cell invasiveness (14).

In summary, these findings indicate that inhibition of DPPIV catalytic activity is associated with inhibition of NHE3-mediated NaHCO\(_3\) reabsorption in the native renal proximal tubule. Inhibition of apical Na\(^{+}\)-H\(^{+}\) exchange results from changes in subcellular localization of NHE3. Moreover, these studies underscore the functional importance of the association between NHE3 and DPPIV in rat renal proximal tubule.

REFERENCES


AJP-Renal Physiol • VOL 294 • FEBRUARY 2008 • www.ajprenal.org

http://ajprenal.physiology.org/


